FDA Keeps Boxed Warning About Suicide On Chantix

WASHINGTON (AP) – The Food and Drug Administration says it will keep a bold-letter warning on Pfizer’s anti-smoking drug Chantix about suicidal behavior and other psychiatric problems.

Pfizer Inc. asked the agency last year to drop the so-called black box warning, pointing to its own analyses that found no difference in psychiatric problems between people taking Chantix and other stop-smoking treatments.

But the FDA said in an online posting Monday that Pfizer’s data did not examine all types of psychiatric problems and had limitations preventing regulators “from drawing reliable conclusions.”

The agency’s decision follows the recommendation of a panel of outside experts, who voted last October to keep the warning on the drug. New York-based Pfizer is expected to complete a larger study of Chantix’s psychiatric side effects in late 2015.

We welcome thoughts and comments from our viewers. We ask that everyone keep their remarks civil and respectful. Postings that contain profanity, racist, or potentially libelous remarks will be deleted. We will delete any commercial postings, as well.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s